• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Trevena

edit

Trevena is focused on the identification of novel GPCR drugs with unique biology designed to deliver high levels of efficacy and/or low side effect potential.

Milestones

edit

• 
  Trevena added Dennis Yamashita as Vice President and Head, Chemistry.
  Posted 6/17/09 at 6:23pm
• 
  Trevena added Mark Strobeck as Chief Business Officer.
  Posted 6/17/09 at 6:23pm
• 
  Trevena added Michael W. Lark as Senior Vice President and Head, Research.
  Posted 6/17/09 at 6:23pm
• 
  Trevena added Maxine Gowen as President and CEO.
  Posted 6/17/09 at 6:23pm
• 
  Trevena received $10M in Grant funding. (8/19/11)
  Posted 8/18/11 at 10:04pm via dowjones.com
• 
  Trevena received $35M in Series B funding. (7/14/10)
  Posted 7/14/10 at 6:14pm via onbiovc.com
• 
  Trevena received $24M in Series A funding. (3/1/08)
  Posted 6/17/09 at 6:23pm via trevenainc.com

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/18/09

Sources

1. Trevena, Inc. Announces $24 Million Series A Financing (trevenainc.com) [edit]
2. Trevena, Inc.: Series B $35M (onbiovc.com) [edit]
3. Trevena Jumps Into Antidepressant Market Through $10M NIH Grant (fis.dowjones.com) [edit]